Single-dose gene-editing therapy VERVE-102 lowers bad cholesterol by up to 62 percent VERVE-102 uses CRISPR base editing to permanently disable PCSK9 gene in liver cells Phase 1b trial showed durable LDL reduction for up to 18 months without serious side effects